Senseonics to Present at BTIG MedTech Conference Amid CGM Market Expansion

Event summary

  • Senseonics will present at BTIG's 13th Annual MedTech Conference on February 11, 2026 in Snowbird, Utah.
  • The company focuses on long-term implantable continuous glucose monitoring (CGM) systems for diabetes management.
  • Senseonics' products include Eversense® 365 and Eversense® E3, featuring a subcutaneous sensor and smartphone app integration.
  • Investors can request meetings through BTIG representatives.

The big picture

Senseonics' participation in the BTIG MedTech Conference underscores the growing importance of continuous glucose monitoring in diabetes management. The company's focus on long-term implantable solutions positions it in a competitive segment dominated by frequent sensor replacements. As the CGM market expands, Senseonics' ability to differentiate its technology and secure regulatory approvals will be critical to its long-term success.

What we're watching

Market Differentiation
How Senseonics' long-term implantable CGM technology will compete against established players like Dexcom and Abbott.
Regulatory Approvals
The pace at which Senseonics secures additional regulatory clearances for its Eversense® products in key markets.
Revenue Growth
Whether Senseonics can sustain its growth trajectory amid increasing competition in the CGM space.